Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cila Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution involves a distinct examiner and 1 distinct art unit. SHOMER, ISAAC is the busiest examiner for the company, managing the 1 pending office action. The focus on a single examiner and art unit for the matter suggests a concentrated legal strategy. This allows for a direct and consistent relationship with SHOMER, ISAAC during the examination process. The 1 distinct art unit provides the specialized technical environment for the pharmaceutical matter.
The Biotechnology & Pharmaceuticals technology area covers the active matter currently pending for the company. Having only a distinct examiner ensures that all feedback is centralized and originates from SHOMER, ISAAC. The 1 distinct art unit indicates that the pending application is being reviewed by a specific group of biotechnology experts. With a single pending office action, the company can focus its resources on resolving the current examiner concerns. This distinct examiner and art unit represent the entirety of the company's current patent office engagement. The pending office action is the sole focus of the company's active prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOMER, ISAAC | 1 | 63.2% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18939439 | AGENTS, COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF NUCLEIC ACIDS TO THE CELLS WITHIN THE RESPIRATORY SYSTEM | SHOMER, ISAAC | 42d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18939439 | AGENTS, COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF NUCLEIC ACIDS TO THE CELLS WITHIN THE RESPIRATORY SYSTEM | SHOMER, ISAAC | 42d overdue |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18939439 | AGENTS, COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF NUCLEIC ACIDS TO THE CELLS WITHIN THE RESPIRATORY SYSTEM | SHOMER, ISAAC | 1612 | §103§112 | Final Rejection | 42d overdue | Pending | Nov 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial